NKTR 181

Drug Profile

NKTR 181

Alternative Names: NKTR181

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Back pain
  • Phase III Pain
  • Phase II Musculoskeletal pain

Most Recent Events

  • 22 Nov 2017 Preregistration for Back pain in USA (PO)
  • 07 Nov 2017 Nektar Therapeutics announces intention to submit NDA to US FDA by April 2018
  • 06 Sep 2017 Interim efficacy data from the phase III SUMMIT-07 trial in Pain released by Nektar Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top